الصفحة الرئيسية>>Signaling Pathways>> Apoptosis>> RIP kinase>>RIPK1-IN-7

RIPK1-IN-7

رقم الكتالوجGC37536

RIPK1-IN-7 هو مثبط RIPK1 قوي وانتقائي مع Kd من 4 نانومتر و IC الإنزيمي لـ 11 نانومتريُظهر RIPK1-IN-7 نشاطًا ممتازًا لورم خبيث في نموذج ورم خبيث في الرئة من سرطان الجلد B16 التجريبي

Products are for research use only. Not for human use. We do not sell to patients.

RIPK1-IN-7 التركيب الكيميائي

Cas No.: 2300982-44-7

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
337٫00
متوفر
5mg
306٫00
متوفر
10mg
490٫00
متوفر
50mg
1530٫00
متوفر
100mg
2244٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

RIPK1-IN-7 is a potent and selective RIPK1 inhibitor with a Kd of 4 nM and an enzymatic IC50 of 11 nM. RIPK1-IN-7 exhibits excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model[1]. IC50: 11 nM (RIPK1)[1]Kd: 4 nM (RIPK1)[1]

RIPK1-IN-7 shows potent cell protection effect in the TSZ-induced HT29 cell necroptosis model with an EC50 of 2nM[1].RIPK1-IN-7 displays considerable activity against several other kinases, such as Flt4, TrkA, TrkB, TrkC, Axl, HRI, Mer, and MAP4K5 with IC50s of 20, 26, 8, 7, 35, 26, 29, and 27 nM, respectively[1].

[1]. Li Y, et al. Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model. J Med Chem. 2018 Dec 27;61(24):11398-11414.

مراجعات

Review for RIPK1-IN-7

Average Rating: 5 ★★★★★ (Based on Reviews and 4 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for RIPK1-IN-7

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.